Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer: early-phase trial registry
423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1 of 28,707 conditions by registered trial count.
1,251 US clinical trials · 423 currently recruiting · #1 of 28,707 conditions by registered trial count
Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.
Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.
Enrollment posture brief
Registry condition breast-cancer
OPEN 423 | RECR 34% | LATE 120 | EARLY 491 | RANK #1 | SPON 98
Volume-matched condition peers
Nearest open-share peer: Refractory Multiple Myeloma (34% recruiting · 68 trials)
Breast Cancer lists 423 open slots (34% of 1,251 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer is recruiting below its size-band peers.
423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.
-
Breast Cancer research is mostly interventional.
1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,251 total, page 19 of 26
A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer
Memorial Sloan Kettering Cancer Center
NCT00984321
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Novartis Pharmaceuticals
NCT01068483
Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health
Memorial Sloan Kettering Cancer Center
NCT01738152
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Syros Pharmaceuticals
NCT04247126
Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer
Puma Biotechnology
NCT00741260
A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer
Eisai
NCT00879086
Cone Beam Computed Tomography for Breast Imaging
Koning Corporation
NCT00972413
Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
SCRI Development Innovations
NCT00193037
Comparing (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer
University of California, San Francisco
NCT01308775
Promotora Navigator - Culturally Appropriate Patient Navigator
Vanderbilt University Medical Center
NCT03557801
Exercise Intervention in Women With Metastatic Breast Cancer
Dana-Farber Cancer Institute
NCT00405782
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Pfizer
NCT01597193
Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions
Memorial Sloan Kettering Cancer Center
NCT02086578
An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer
University of Kansas
NCT00291122
Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial
Yale University
NCT02256670
Intensity Modulated Radiotherapy for Breast Cancer
Washington University School of Medicine
NCT00594477
Safety Study of the Hypo-fractionated (Large Doses) Radiation Therapy in Post-menopausal Women With Breast Cancers
NYU Langone Health
NCT02883985
Improving Adherence to Recommended Surveillance in Breast Cancer Survivors
Duke University
NCT02189278
Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program
Fujifilm Medical Systems USA
NCT02685566
Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer
NCIC Clinical Trials Group
NCT00066586
Inflammation-Induced CNS Glutamate During Breast Cancer Treatment
Emory University
NCT02421978
Team Based Psychosocial Care to Promote, Maintain and Restore Wellness of Breast Cancer Patients
Mayo Clinic
NCT03770598
Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy
Mayo Clinic
NCT01777802
Magnetic Resonance Imaging in Patients With Breast Cancer
M.D. Anderson Cancer Center
NCT00610181
S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
SWOG Cancer Research Network
NCT00015938
Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer
COL George Peoples, MD, FACS
NCT00854789
Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer
Puma Biotechnology
NCT00706030
Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery
M.D. Anderson Cancer Center
NCT00542542
Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
Yale University
NCT00002679
A Cost-Effective Handheld Breast Scanner for Use in Low Resource Environments: A Validation Study
University of Pennsylvania
NCT02814292
Physician-Patient Communication About Breast Cancer-Related Internet Information and Its Effect on Patient Satisfaction and Anxiety
Memorial Sloan Kettering Cancer Center
NCT00712569
A Web-Based Tool to Improve Breast Cancer Survivorship
Northwestern University
NCT03849573
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
BBB-Therapeutics B.V.
NCT01386580
Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial
Dana-Farber Cancer Institute
NCT03783546
Eribulin in HER2 Negative Metastatic BrCa
Dana-Farber Cancer Institute
NCT01827787
Cytokine Expression During Radiation for Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00836186
Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification
Memorial Sloan Kettering Cancer Center
NCT02177175
Enhancing Exercise in Breast Cancer Survivors
Duke University
NCT01849978
Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer
University of California, San Francisco
NCT00755313
Mobile Health App to Promote Participation of Black Women in Breast Cancer Clinical Trials
UNC Lineberger Comprehensive Cancer Center
NCT06361056
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Marker Therapeutics
NCT02593227
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
National Cancer Institute (NCI)
NCT00001302
Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer
SCRI Development Innovations
NCT00405938
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
Emory University
NCT01271738
Evaluating the Effectiveness of an Individualized Nutrition and Physical Activity Counseling Program
Case Comprehensive Cancer Center
NCT04365569
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Eisai
NCT01439282
Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer
Translational Oncology Research International
NCT00217672
Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)
University of California, San Francisco
NCT00804128
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
University of Alabama at Birmingham
NCT00530868
A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
Genentech
NCT03916744
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 235 |
| Phase 2 | 256 |
| Phase 3 | 100 |
| Phase 4 | 20 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Cancer page
1,251 registered trials, 423 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 423 Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer condition card totals 1,251 registered trials; most-linked intervention Fulvestrant; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.